Monitoring, evaluation and comparison of adverse effect profile of ciprofloxacin and ofloxacin in acute bacterial exacerbation of chronic bronchitis patients attending pulmonology department of tertiary care teaching hospital: a prospective observational study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20181177Keywords:
ABECB, Ciprofloxacin, Insomnia, OfloxacinAbstract
Background: In 2016, FDA recommended that “serious side effects associated with flouroquinolones generally outweigh the benefits for the patients with acute sinusitis, acute bronchitis and uncomplicated UTI”. Throughout India the most commonly used flouroquinolones for above conditions are Ciprofloxacin, Ofloxacin, and Levofloxacin. In this scenario, the present study was undertaken to monitor, evaluate and compare the adverse effect profile of Ciprofloxacin and Ofloxacin in acute exacerbation of chronic bronchitis patients.
Methods: Prospective, observational study done in 200 patients of tertiary care teaching hospital. The patients diagnosed with, acute bronchitis treated with Ciprofloxacin 500mg BD or Ofloxacin 400mg BD for 7 days were included in the study. The study duration was 6 months. ADR causality assessment was done with Naranjo algorithm. Statistical test applied was chi- square test.
Results: 63 ADR were reported in Ofloxacin group and 19 ADR in Ciprofloxacin group. Insomnia was most frequent ADR (40%) in patients treated with Ofloxacin. There is high incidence of ADRs in ofloxacin group. chi square test showed this difference is statistically significant (p<0.05). Insomnia was significantly higher in ofloxacin group (p<0.05).
Conclusions: In India frequently used and misused antimicrobials are fluoroquinolones. The present study concluded that no serious ADRs but ofloxacin group of patients have shown increased incidence of ADRs associated with CNS especially Insomnia. However, further large scale, multi-centric studies are needed to confirm these results.
References
Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis. 2002; 35:1505-11.
Oreagba IA, Oshikoya KA, Ogar C, Adefwin AO, Ibrahim A, Awodele O, et al. Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016. Pharmacol Res Perspect. 2017 Apr;5(2):e00297.
Tytler BA, Mijinyawa N, Ida A. Comparative quality of fluoroquinolone tablets marketed in some towns in Northern Nigeria. J Pharm Bioresources. 2007;4:8-13.
Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf. 2013;12:497-505.
Halkin H. Adverse effects of the fluoroquinolones. RevInfect Dis. 1988; 10: S258–S261.
De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones: an overview on mechanistic aspects. Curr Med Chem. 2001;8:371-84.
Norrby SR. Side-effects of quinolones: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis. 1991;000:378-83.
Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy. 2001;21(10 Pt 2):253-72S.
de Bazignan AD, Thiessard F, Miremont-Salame´ G. Psychiatric adverse effects of fluoroquinolones: review of cases from the French pharmacologic surveillance database. Rev Med Interne 2006;27(6):448-52.
De Sarro A, Cecchetti V, Fravolini V, Naccari F, Tabarrini, De Sarro G. Effects of novel 6-Desfluoroquinolones and Classic Quinolones on pentylenetetrazole-induced Seizures in Mice”. Antimicrob Agents Chemother. 1999;43(7):1729-36.
Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U. Possible interaction of Fluroquinolones with the benzodiazepine-GABA A –Receptor complex. July 1990;30(1):63-70.
